National Medical Products Administration: By early 2030, establish an innovative system integrating drug regulation and artificial intelligence.

People’s Finance Information, April 2: On April 2, the National Medical Products Administration issued the Implementation Opinions on “Artificial Intelligence + Drug Regulation.” The Opinions propose that by 2030, a drug regulation and artificial intelligence integration and innovation system will be initially established. The operational management mechanism for “Artificial Intelligence + Drug Regulation” will be basically in place. The support base for computing power will become more centralized and efficient. High-quality datasets, vertical large models, and intelligent agents will be developed to meet the needs of intelligent regulation. Artificial intelligence will be effectively applied in scenarios such as review and approval, supervision and inspection, testing and monitoring, and government services, with a significant improvement in human-machine collaboration efficiency. The capabilities for full-lifecycle digital and intelligent regulation will reach a new level. By 2035, a new pattern of intelligent drug safety governance driven by digital intelligence, characterized by agility, self-reliance and controllability, and ecosystem collaboration, will be fundamentally formed.